SML3739
AZ Dyrk1B 33
≥98% (HPLC)
Synonym(s):
3-(2-Methyl-4-pyrimidinyl)-1-(phenylmethyl)-1H-pyrrolo[2,3-c]pyridine, AZ-Dyrk1B-33
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C19H16N4
CAS Number:
Molecular Weight:
300.36
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Related Categories
Biochem/physiol Actions
Potent and selective Dyrk1B kinase inhibitor that increased the number of incretin-expressing cells in diabetic mice.
AZ Dyrk1B 33 is a potent and selective Dyrk1B kinase (dual-specificity tyrosine phosphorylation-regulated kinase 1B) inhibitor. AZ Dyrk1B 33 potently increases the numbers of neurogenin 3-expressing enteroendocrine progenitors, Gip-expressing K-cells, and Glp-1-expressing L-cells in zebrafish and diabetic mice. It decreases glucose levels in both larval and juvenile zebrafish.
AZ Dyrk1B 33 is a potent and selective Dyrk1B kinase (dual-specificity tyrosine phosphorylation-regulated kinase 1B) inhibitor. AZ Dyrk1B 33 potently increases the numbers of neurogenin 3-expressing enteroendocrine progenitors, Gip-expressing K-cells, and Glp-1-expressing L-cells in zebrafish and diabetic mice. It decreases glucose levels in both larval and juvenile zebrafish.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Lianhe Chu et al.
Cell chemical biology, 29(9), 1368-1380 (2022-08-24)
Analogs of the incretin hormones Gip and Glp-1 are used to treat type 2 diabetes and obesity. Findings in experimental models suggest that manipulating several hormones simultaneously may be more effective. To identify small molecules that increase the number of
Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis
Journal of medicinal chemistry, 58(6), 2834-2844 (2015)
Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleus
Bioorganic & Medicinal Chemistry Letters, 27(11), 2617-2621 (2017)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service